Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COURAGE: Vibegron in Men with OAB and BPH
NCT03902080Phase 3Completed
- Sponsor
- Urovant Sciences
- Start
- Mar 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing Vibegron 75 mg with Placebo (2 arms). Primary endpoints: Change From Baseline in the Average Number of Micturition Episodes Per Day at 12 weeks and Change From Baseline in the Average Number of Urgency Episodes Per Day at 12 weeks. Started Mar 2019; status: completed.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT03902080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902080.